Expansion Therapeutics
Andy Phillips, Ph. D. is a Managing Director at Cormorant Asset Management, LP (“Cormorant”). Before joining Cormorant, Andy was the President and Chief Executive Officer of C4 Therapeutics. Prior to C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at the Broad Institute. Previously, he was a Professor of Chemistry at Yale University and a Professor of Chemistry and Biochemistry at the University of Colorado. Andy holds Ph.D. and B.Sc. Hons. degrees in Biochemistry and Chemistry from the University of Canterbury (Christchurch, New Zealand).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Expansion Therapeutics
2 followers
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.